May 24 | 2022
2cureX offentliggör delårsrapport för det första kvartalet 2022
Read more
May 12 | 2022
2cureX AB nominates Dr. Michael Schaefer to the Board of Directors
Read more
May 12 | 2022
2cureX AB nominerar Dr. Michael Schaefer till styrelsen
Read more
May 6 | 2022
2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Read more
May 6 | 2022
2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie
Read more
May 3 | 2022
2cureX publishes the annual report for the fiscal year 2021
Read more
May 3 | 2022
2cureX offentliggör årsredovisning för räkenskapsåret 2021
Read more
April 29 | 2022
Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022
Read more
April 22 | 2022
Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022
Read more
April 22 | 2022
Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022
Read more
April 21 | 2022
Notice of annual general meeting of 2cureX AB (publ)
Read more
April 21 | 2022
Kallelse till årsstämma i 2cureX AB
Read more
March 14 | 2022
2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022
Read more
February 24 | 2022
2cureX publishes interim report for the fourth quarter and all 12 months of 2021
Read more
February 24 | 2022
2cureX offentliggör delårsrapport för det fjärda kvartalen och alla tolv månader 2021
Read more
January 21 | 2022
New Institutional shareholder
Read more
January 11 | 2022
IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica
Read more
January 5 | 2022
IndiTreat® to be distributed in Poland by Perlan Technologies
Read more